Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
Amgen and Zai Lab eye a gastric niche
Adverse events will be closely watched when full data are reported.
Amgen looks for Five Prime payback
A key pivotal study of bemarituzumab will read out shortly.
